EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti–PD-1 resistance

Ashwin Ajith, Kenza Mamouni, Daniel D Horuzsko, Abu Musa, Amiran K Dzutsev, Jennifer R Fang, Ahmed Chadli, Xingguo Zhu, Iryna Lebedyeva, Giorgio Trinchieri, Anatolij Horuzsko

Journal of Clinical Investigation · 01.11.2023 · 133 (21)

DOI: 10.1172/jci167951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.11.2023. Verfasst von Ashwin Ajith und 10 weiteren Autor:innen. Beteiligte Einrichtung: Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Melanoma. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Derived Suppressor CellsMelanomaHumansAnimalsMiceTriggering Receptor Expressed on Myeloid Cells-1Myeloid CellsCell Line, TumorT-Lymphocytes, CytotoxicDisease Models, AnimalTumor Microenvironment

Stichwörter der Autor:innen

Cancer immunotherapyCellular immune responseMelanomaOncologyTherapeutics

Substanzen

Triggering Receptor Expressed on Myeloid Cells-1TREM1 protein, humanTREM1 protein, mouse

Autor:innen und Institutionen

  • Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Chemistry and Physics, Augusta University, Augusta, Georgia, USA.

Förderung

  • NCI NIH HHS
  • NIH/NCI

Zitieren

APA

Ajith, A., Mamouni, K., Horuzsko, D. D., Musa, A., Dzutsev, A. K., Fang, J. R., Chadli, A., Zhu, X., Lebedyeva, I., Trinchieri, G., & Horuzsko, A. (2023). Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti–PD-1 resistance. Journal of Clinical Investigation, 133(21). https://doi.org/10.1172/jci167951

Vancouver

Ajith A, Mamouni K, Horuzsko DD, Musa A, Dzutsev AK, Fang JR, et al. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti–PD-1 resistance. Journal of Clinical Investigation. 2023;133(21). doi:10.1172/jci167951

BibTeX
@article{Ajith2023,
  author = {Ajith, Ashwin and Mamouni, Kenza and Horuzsko, Daniel D and Musa, Abu and Dzutsev, Amiran K and Fang, Jennifer R and Chadli, Ahmed and Zhu, Xingguo and Lebedyeva, Iryna and Trinchieri, Giorgio and Horuzsko, Anatolij},
  title = {Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti–PD-1 resistance},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {21},
  doi = {10.1172/jci167951}
}
Kostenlos starten →